Nuclear Medicine Clinic, Zentralklinik Bad Berka, Germany.
Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Clin Nucl Med. 2021 Dec 1;46(12):1030-1031. doi: 10.1097/RLU.0000000000003792.
Somatostatin receptor-targeted α-therapy using α-emitter 225Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with β-emitters, such as 177Lu or 90Y. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with β-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remission, as well as significantly improved clinical symptoms) after 225Ac-DOTATOC-targeted α-therapy, without any adverse effects during the treatment or in the follow-up period.
使用 α 发射体 225Ac 标记的生长抑素类似物进行生长抑素受体靶向 α 治疗，已被提议作为治疗晚期转移性神经内分泌肿瘤 (NET) 的一种选择，这些 NET 对 β 发射器（如 177Lu 或 90Y）的治疗失败。胸腺 NET 很少见，通常比其他神经内分泌肿瘤实体更具侵袭性。我们在此介绍一例β射线难治性转移性胸腺 NET 病例，该患者在接受 225Ac-DOTATOC 靶向 α 治疗后表现出极好的治疗反应（分子和形态学缓解，以及显著改善的临床症状），在治疗期间或随访期间没有任何不良反应。
